Atalanta Therapeutics Has Rebranded as Arexera Therapeutics
The Boston-based firm plans to begin Phase 1 trials for its Huntington's disease drug candidate by the end of 2026.
Updated on Oct. 14, 2026 in Biotech
Live Poll
Are pharmaceutical companies doing enough to develop new treatments for rare neurodegenerative diseases?
Boston-based biotechnology firm Atalanta Therapeutics has officially rebranded as Arexera Therapeutics. The company is currently developing ATL-101, an investigational siRNA therapy targeting the HTT gene to treat Huntington's disease.
Why it matters
The rebrand signals a refined strategic focus as the company prepares to move its lead candidate into clinical trials. Arexera aims to utilize its proprietary siRNA platforms to develop potential disease-modifying treatments for patients suffering from Huntington's disease.
Arexera Therapeutics has raised $150 million to advance its proprietary siRNA platforms, which are engineered to enable gene silencing in the brain. The company is currently targeting the HTT gene, which contains an expanded CAG repeat in Huntington's disease patients.
The players
Arexera Therapeutics
This Boston-based biotechnology company focuses on developing siRNA-based gene-silencing therapies for neurodegenerative diseases.
Genentech
This biotechnology corporation maintains a strategic collaboration with Arexera Therapeutics to advance therapeutic development.
The details
The firm employs divalent and bispecific siRNA platforms designed to reduce expression of the HTT gene, with preclinical results showing successful suppression in the deep brain of non-human primates. In addition to ATL-101, the company is researching MSH3-targeting monotherapies and dual-targeting strategies while maintaining a collaboration with Genentech.
Timeline
October 14, 2026: The company formally announced its rebranding to Arexera Therapeutics.
End of 2026: Arexera plans to initiate its first Phase 1 clinical study for ATL-101.
The Tech Race
The company's focus on siRNA therapeutic platforms highlights the ongoing industry transition toward gene-silencing treatments for neurodegenerative conditions. This shift reflects a broader technological effort to replace legacy small-molecule approaches with precise genetic interventions.
The transition to a clinical trial phase represents a potential step toward new therapeutic options for the 40,000 Americans currently living with symptomatic Huntington's disease. Patients and their families should monitor updates from the company as the 2026 trial initiation date approaches.
The takeaway
The rebranding to Arexera Therapeutics signals the company's transition from a research-focused entity into a clinical-stage developer. Readers should follow future regulatory filings to track the progress of the ATL-101 program.
What happens next
Arexera Therapeutics expects to begin its Phase 1 clinical trial for the drug candidate ATL-101 by the end of 2026.
Further reading
Learn more about the local industry by visiting our Biotech section.
More information
For more information, visit the Arexera Therapeutics corporate website.
Source note: This article includes information reported by The Manila times.
Live Poll
Are pharmaceutical companies doing enough to develop new treatments for rare neurodegenerative diseases?
